149 related articles for article (PubMed ID: 36610075)
1. Flexible evaluation of surrogacy in platform studies.
Sachs MC; Gabriel EE; Crippa A; Daniels MJ
Biostatistics; 2023 Dec; 25(1):220-236. PubMed ID: 36610075
[TBL] [Abstract][Full Text] [Related]
2. Comparing Bayesian hierarchical meta-regression methods and evaluating the influence of priors for evaluations of surrogate endpoints on heterogeneous collections of clinical trials.
Collier W; Haaland B; Inker LA; Heerspink HJL; Greene T
BMC Med Res Methodol; 2024 Feb; 24(1):39. PubMed ID: 38365599
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. Comparing biomarkers as trial level general surrogates.
Gabriel EE; Daniels MJ; Halloran ME
Biometrics; 2016 Dec; 72(4):1046-1054. PubMed ID: 27038302
[TBL] [Abstract][Full Text] [Related]
5. Optimizing and evaluating biomarker combinations as trial-level general surrogates.
Gabriel EE; Sachs MC; Daniels MJ; Halloran ME
Stat Med; 2019 Mar; 38(7):1135-1146. PubMed ID: 30306600
[TBL] [Abstract][Full Text] [Related]
6. Surrogacy assessment using principal stratification with multivariate normal and Gaussian copula models.
Taylor JM; Conlon AS; Elliott MR
Clin Trials; 2015 Aug; 12(4):317-22. PubMed ID: 25490988
[TBL] [Abstract][Full Text] [Related]
7. A Bayesian approach to improved estimation of causal effect predictiveness for a principal surrogate endpoint.
Zigler CM; Belin TR
Biometrics; 2012 Sep; 68(3):922-32. PubMed ID: 22348277
[TBL] [Abstract][Full Text] [Related]
8. Bayesian hierarchical meta-analytic methods for modeling surrogate relationships that vary across treatment classes using aggregate data.
Papanikos T; Thompson JR; Abrams KR; Städler N; Ciani O; Taylor R; Bujkiewicz S
Stat Med; 2020 Apr; 39(8):1103-1124. PubMed ID: 31990083
[TBL] [Abstract][Full Text] [Related]
9. Surrogacy assessment using principal stratification when surrogate and outcome measures are multivariate normal.
Conlon AS; Taylor JM; Elliott MR
Biostatistics; 2014 Apr; 15(2):266-83. PubMed ID: 24285772
[TBL] [Abstract][Full Text] [Related]
10. Causal assessment of surrogacy in a meta-analysis of colorectal cancer trials.
Li Y; Taylor JM; Elliott MR; Sargent DJ
Biostatistics; 2011 Jul; 12(3):478-92. PubMed ID: 21252079
[TBL] [Abstract][Full Text] [Related]
11. Bayesian adjusted R2 for the meta-analytic evaluation of surrogate time-to-event endpoints in clinical trials.
Renfro LA; Shi Q; Sargent DJ; Carlin BP
Stat Med; 2012 Apr; 31(8):743-61. PubMed ID: 22161275
[TBL] [Abstract][Full Text] [Related]
12. Bivariate network meta-analysis for surrogate endpoint evaluation.
Bujkiewicz S; Jackson D; Thompson JR; Turner RM; Städler N; Abrams KR; White IR
Stat Med; 2019 Aug; 38(18):3322-3341. PubMed ID: 31131475
[TBL] [Abstract][Full Text] [Related]
13. Predictive cluster level surrogacy in the presence of interference.
Gabriel EE; Follmann DA
Biostatistics; 2020 Apr; 21(2):e33-e46. PubMed ID: 30247535
[TBL] [Abstract][Full Text] [Related]
14. Flexible evaluation of surrogate markers with Bayesian model averaging.
Duan Y; Parast L
Stat Med; 2024 Feb; 43(4):774-792. PubMed ID: 38081586
[TBL] [Abstract][Full Text] [Related]
15. Accommodating missingness when assessing surrogacy via principal stratification.
Elliott MR; Li Y; Taylor JM
Clin Trials; 2013; 10(3):363-77. PubMed ID: 23553326
[TBL] [Abstract][Full Text] [Related]
16. Surrogacy assessment using principal stratification and a Gaussian copula model.
Conlon A; Taylor J; Elliott MR
Stat Methods Med Res; 2017 Feb; 26(1):88-107. PubMed ID: 24947559
[TBL] [Abstract][Full Text] [Related]
17. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
[TBL] [Abstract][Full Text] [Related]
18. Intermediate markers as surrogate endpoints in cancer research.
Schatzkin A
Hematol Oncol Clin North Am; 2000 Aug; 14(4):887-905. PubMed ID: 10949779
[TBL] [Abstract][Full Text] [Related]
19. Assessing the value of a censored surrogate outcome.
Parast L; Tian L; Cai T
Lifetime Data Anal; 2020 Apr; 26(2):245-265. PubMed ID: 30980316
[TBL] [Abstract][Full Text] [Related]
20. Use of copula to model within-study association in bivariate meta-analysis of binomial data at the aggregate level: A Bayesian approach and application to surrogate endpoint evaluation.
Papanikos T; Thompson JR; Abrams KR; Bujkiewicz S
Stat Med; 2022 Nov; 41(25):4961-4981. PubMed ID: 35932152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
